Kadimastem Granted European Patent for Its
Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
The Patent in Europe Strengthens the Protection of the Company’s Technology in the Diabetes Field
Ness Ziona, Israel, May 15, 2023 Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has been granted a patent from the European Patent Office for its cell therapy technology. IsletRx has been granted its fourth global patent approval for the company's innovative cell selection and enrichment technology, the company's treatment and potential cure for diabetes.
The ability to select and enrich only the highest functioning and purest islet cells from the expanded and differentiated population of pluripotent stem cells enables the maximum therapeutic effect.
Asaf Shiloni the CEO of Kadimastem stated: “The granting of this patent provides the crucial protection to our core Islet cells sorting technology, that is critical to achieve an effective cell therapy product for the treatment of diabetes. The European market holds great potential for our technology.”
According to the International Diabetes Federation in 2021 “the Europe Region has the highest number of children and adolescents with type 1 diabetes – 295,000. Diabetes-related expenditure in the Europe Region totals USD 189 billion – 19.6% of its global expenditure. The Europe Region has the second highest average cost per person with diabetes (20-79y) – USD 3,086”[1].
In May 2021, the selection technology covered by this patent was described in a peer-reviewed journal article[2] in Frontiers in Endocrinology.
Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.
IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes.
Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).
About IsletRx
The IsletRx product is a clinical-grade collection of pancreatic islet cells. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). In addition, the method of production and selection of the cells enables their implantation in various types of smaller size devices, suitable for maximum comfort for people living with diabetes.
Forward Looking Statement
This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future.
Company Contacts:
Asaf Shiloni
CEO